Latest news with #Axogen
Yahoo
a day ago
- Business
- Yahoo
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21
Axogen, Inc. (NASDAQ:AXGN) is one of the . On August 6, Raymond James analyst Jayson Bedford lowered the firm's price target on Axogen, Inc. (NASDAQ:AXGN) to $20 from $21, keeping an Outperform rating on the shares. An orthopedic surgeon connecting peripheral nerves with AxoGuard Nerve Connector, showing the precision and care of AxoGuard's products. The analyst told investors in a research note that Axogen, Inc.'s (NASDAQ:AXGN) Q2 results exhibited a step-up in momentum, with gross margin and revenue growth both demonstrating an improvement. He added that while the low end of H2 guidance points towards a growth deceleration, it appears to be conservative given recent trends and contribution from newly added reps. Axogen, Inc. (NASDAQ:AXGN) develops and markets surgical solutions for peripheral nerve regeneration and repair. The company's products include avive soft tissue membrane, acroval neurosensory and motor testing system, avance nerve graft, axoguard nerve connector, axoguard nerve protector, and more. While we acknowledge the potential of AXGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Axogen Second Quarter 2025 Earnings: Beats Expectations
Explore Axogen's Fair Values from the Community and select yours Axogen (NASDAQ:AXGN) Second Quarter 2025 Results Key Financial Results Revenue: US$56.7m (up 18% from 2Q 2024). Net income: US$579.0k (up from US$1.92m loss in 2Q 2024). Profit margin: 1.0% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. EPS: US$0.013 (up from US$0.044 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Axogen Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 7.7%. Earnings per share (EPS) also surpassed analyst estimates. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are up 9.7% from a week ago. Risk Analysis You should learn about the 1 warning sign we've spotted with Axogen. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
04-07-2025
- Business
- Yahoo
Axogen Showcases Nerve Repair Vision at Goldman Sachs
Axogen, Inc. (NASDAQ:AXGN) is among the best growth stocks to invest in for the next 5 years. On June 11, 2025, Axogen, Inc. (NASDAQ:AXGN) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where a strategic vision was highlighted that is focused on solidifying the company's leadership in nerve repair solutions. The management remains confident about the giant's position in delivering strong growth while expanding the product portfolio. The company is undergoing a wave of transformative operational changes by adding new clinical application areas. With that being said, Axogen, Inc. (NASDAQ:AXGN) is working towards improving professional education activities and entering new areas. An orthopedic surgeon connecting peripheral nerves with AxoGuard Nerve Connector, showing the precision and care of AxoGuard's products. The future outlook of Axogen, Inc. (NASDAQ:AXGN) looks equally promising. The company aims to expand internationally by 2026, with sustained investments in Avance and complementary products, targeting regeneration and protection devices. It doesn't stop there; recognizing significant under-penetration in its existing markets, the company is committed to accelerating growth by advancing its commercial footprint and development initiatives. Axogen, Inc. (NASDAQ:AXGN) is a Florida-based company that develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's core offerings include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and AxoGuard HA+ Nerve Protector. Founded in 2002, the company is focused on improving patients' lives. While we acknowledge the potential of AXGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Axogen Showcases Nerve Repair Vision at Goldman Sachs
Axogen, Inc. (NASDAQ:AXGN) is among the best growth stocks to invest in for the next 5 years. On June 11, 2025, Axogen, Inc. (NASDAQ:AXGN) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where a strategic vision was highlighted that is focused on solidifying the company's leadership in nerve repair solutions. The management remains confident about the giant's position in delivering strong growth while expanding the product portfolio. The company is undergoing a wave of transformative operational changes by adding new clinical application areas. With that being said, Axogen, Inc. (NASDAQ:AXGN) is working towards improving professional education activities and entering new areas. An orthopedic surgeon connecting peripheral nerves with AxoGuard Nerve Connector, showing the precision and care of AxoGuard's products. The future outlook of Axogen, Inc. (NASDAQ:AXGN) looks equally promising. The company aims to expand internationally by 2026, with sustained investments in Avance and complementary products, targeting regeneration and protection devices. It doesn't stop there; recognizing significant under-penetration in its existing markets, the company is committed to accelerating growth by advancing its commercial footprint and development initiatives. Axogen, Inc. (NASDAQ:AXGN) is a Florida-based company that develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's core offerings include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and AxoGuard HA+ Nerve Protector. Founded in 2002, the company is focused on improving patients' lives. While we acknowledge the potential of AXGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-05-2025
- Business
- Associated Press
Axogen, Inc. Reports 2025 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results 'We are pleased with our first quarter 2025 results and progress to date towards our longer-term objectives as described during our March 4th, 2025 Investor Day. Our revenue growth remains robust across our full range of nerve repair and protection solutions, driven by enhanced sales productivity and commercial execution.' commented Michael Dale, CEO and Director of Axogen, Inc. 'With one quarter behind us into the new year, we remain confident our market development objectives and business model optimization plans remain the right priorities for fulfillment of our business purpose to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care.' Summary of Business Highlights 2025 Financial Guidance We are maintaining our full year revenue growth guidance in the range of 15% to 17% and continue to expect gross margin to be in the range of 73% to 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%. Additionally, we reiterate that we expect to be net cash flow positive for the full year. Conference Call The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the Company's website at and clicking on the webcast link. Following the conference call, a replay will be available in the Investors section of the Company's website at under Investors. About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine (pig) submucosa extracellular matrix ('ECM') coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue healing. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea and several other countries. For more information, visit Cautionary Statements Concerning Forward-Looking Statements This press release contains 'forward-looking' statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as 'expects,' 'anticipates,' 'priorities,' 'objectives,' 'targets,' 'intends,' 'plan(s),' 'believes,' 'seeks,' 'estimates,' 'projects,' 'forecasts,' 'continue,' 'may,' 'should,' 'will,' 'goals,' and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our business model optimization plans, market development objectives, our business purpose to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care, and our expectation of BLA approval in September 2025, as well as statements under the subheading '2025 Financial Guidance.' Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions from leadership transitions, global supply chain issues, record inflation, hospital staffing challenges, product development timelines, product potential, expected clinical enrollment timing and outcomes, regulatory processes and approvals, financial performance, sales growth, surgeon and product adoption rates, market awareness of our products, data validation processes, our visibility at and sponsorship of conferences and educational events, global business disruption from Russia's invasion of Ukraine and related sanctions, recent geopolitical conflicts in the Middle East, the evolving macroeconomic environment (including financial market volatility), geopolitical tensions, and escalating trade disputes with U.S. trading partners, as well as those risk factors described under Part I, Item 1A., 'Risk Factors,' in our Annual Report on Form 10-K for the year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes noncash stock compensation expense. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share - basic and diluted which excludes noncash stock compensation expense from Net Income or Loss and Net Income or Loss Per Common Share - basic and diluted, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business. Contact: Axogen, Inc. [email protected]
